What does DSIP do? Benefits and evidence

DSIP is a nine-amino-acid peptide studied mainly in small, older experiments. Early sleep reports were positive, but controlled insomnia studies found little clinical benefit. Online injection and nasal routines are not established sleep treatments. Low blood pressure occurred in an IV study, and product quality adds risk.

• In small early studies, people slept longer with fewer wake-ups, but later controlled insomnia studies found little benefit. (Studied in a trial)
• In an older study with no placebo group, withdrawal signs eased or went away in 97% of opioid and 87% of alcohol patients. (Studied in a trial)
• People report deeper sleep or fewer wake-ups at night, though others notice no benefit or even worse sleep. (Reported by users)
• In a tiny pilot with no placebo group, 6 of 7 people in pain had lower pain scores, and their low mood also improved. (Studied in a trial)

Uses in the sources

• Studied for chronic insomnia. Small early reports were positive; the 1987 and 1992 controlled studies found little clinical benefit. (Studied in a trial) (source)
• Studied for alcohol and opioid withdrawal in uncontrolled inpatient studies. Results do not establish a home withdrawal regimen. (Studied in a trial) (source)
• A narcolepsy case and a seven-person pain pilot reported improvement; neither establishes effectiveness. (Studied in a trial) (source)
• Nasal preparations were studied for retinal responses in diabetes. These reports did not test insomnia. (Studied in a trial) (source)
• People report bedtime injections, intermittent nasal use and cycles. Benefits range from better sleep to no effect or worse insomnia. (Reported by users) (source)